文献速递淋巴瘤

经典型霍奇金淋巴瘤患者肺部疾病相对匹配背景人群:一项丹麦全国队列研究

Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
PubMed 文献 · Br J Haematol · 2024-04-29

该丹麦全国队列研究纳入2000至2018年间接受ABVD或BEACOPP治疗的1474例成人经典型霍奇金淋巴瘤患者及7370例年龄性别匹配对照。中位随访8.6年,患者发生肺部疾病风险升高(HR 2.91,95%CI 2.30-3.68),10年累积风险7.4%对2.9%,间质性肺病和慢性阻塞性肺病风险亦升高,哮喘无超额风险。

要点

  • 经典型霍奇金淋巴瘤患者发生肺部疾病风险升高(HR 2.91,95%CI 2.30-3.68)。
  • 间质性肺病风险显著升高(HR 15.84,95%CI 9.35-26.84),10年累积风险4.1%。
  • 慢性阻塞性肺病风险升高(HR 1.99,95%CI 1.43-2.76),10年累积风险3.5%。

核心结论

  • 研究记录到经典型霍奇金淋巴瘤患者中肺部疾病负担显著,并强调对肺部症状进行诊断性检查的重要性。

研究设计与样本

  • 丹麦全国性人群队列研究,纳入2000至2018年间接受ABVD或BEACOPP治疗的1474例成人经典型霍奇金淋巴瘤患者及7370例年龄性别匹配的背景人群对照。
  • 患者中位随访8.6年。

主要发现

  • 经典型霍奇金淋巴瘤患者发生肺部疾病风险升高(HR 2.91,95%CI 2.30-3.68),10年累积风险7.4%对2.9%。
  • 间质性肺病风险升高(HR 15.84,95%CI 9.35-26.84),10年累积风险4.1%。
  • 慢性阻塞性肺病风险升高(HR 1.99,95%CI 1.43-2.76),10年累积风险3.5%。
  • 哮喘无超额风险(HR 0.82,95%CI 0.43-1.56)。
  • 间质性肺病的危险因素包括年龄≥60岁、存在B症状和低白蛋白。

临床怎么用

  • 原文结论强调对经典型霍奇金淋巴瘤患者的肺部症状进行诊断性检查的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin-containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population-based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age- and sex-matched comparators from the background population. Median follow-up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30-3.68]), with a 10-year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35-26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43-2.76]), with a 10-year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43-1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B-symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work-up of pulmonary symptoms.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Vandtved JH, Øvlisen AK, Baech J, et al. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study. Br J Haematol. 2024. PMID: 38685596. doi:10.1111/bjh.19475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。